Management raised fiscal 2025 EPS guidance to $7.85-$8, a $0.10 increase at the midpoint, reflecting strong Pharma performance and contributions from recent acquisitions. The company expects Q3 to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback